;PMID: 11329794
;source_file_976.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..43] = [t:0..43]
;1)sentence:[e:49..150] = [t:49..150]
;2)section:[e:154..175] = [t:154..175]
;3)section:[e:179..192] = [t:179..192]
;4)section:[e:196..254] = [t:196..254]
;5)sentence:[e:258..384] = [t:258..384]
;6)sentence:[e:385..497] = [t:385..497]
;7)sentence:[e:498..596] = [t:498..596]
;8)sentence:[e:597..785] = [t:597..785]
;9)sentence:[e:786..914] = [t:786..914]
;10)sentence:[e:915..1044] = [t:915..1044]
;11)sentence:[e:1045..1196] = [t:1045..1196]
;12)sentence:[e:1197..1395] = [t:1197..1395]
;13)sentence:[e:1396..1512] = [t:1396..1512]
;14)sentence:[e:1514..1601] = [t:1514..1601]
;15)sentence:[e:1602..1708] = [t:1602..1708]
;16)sentence:[e:1709..1853] = [t:1709..1853]
;17)sentence:[e:1854..1992] = [t:1854..1992]
;18)sentence:[e:1993..2105] = [t:1993..2105]
;19)section:[e:2109..2127] = [t:2109..2127]
;20)section:[e:2133..2139] = [t:2133..2139]
;21)section:[e:2145..2161] = [t:2145..2161]
;22)section:[e:2165..2210] = [t:2165..2210]

;section 0 Span:0..43
;Gan To Kagaku Ryoho. 2001 Apr;28(4):549-60.
(SEC
  (FRAG (VBG:[0..3] Gan) (TO:[4..6] To) (VB:[7..13] Kagaku) (NNP:[14..19] Ryoho)
        (.:[19..20] .) (CD:[21..25] 2001) (CC:[26..33] Apr;28-LRB-)
        (CD:[33..35] 4-RRB-) (CD:[35..39] :549) (HYPH:[39..40] -)
        (CD:[40..42] 60) (.:[42..43] .)))

;sentence 1 Span:49..150
;[Development of a novel aromatase inhibitor, anastrozole (Arimidex)--its
;basic  and clinical studies]
;[73..82]:cyp450:"aromatase"
;[83..92]:substance:"inhibitor"
;[94..105]:substance:"anastrozole"
;[107..115]:substance:"Arimidex"
(SENT
  (NP-HLN (-LRB-:[49..50] -LSB-)
    (NP
      (NP (NN:[50..61] Development))
      (PP (IN:[62..64] of)
        (NP
          (NP (DT:[65..66] a) (JJ:[67..72] novel) (NN:[73..82] aromatase)
              (NN:[83..92] inhibitor))
          (,:[92..93] ,)
          (NP
            (NP (NN:[94..105] anastrozole))
            (NP (-LRB-:[106..107] -LRB-) (NN:[107..115] Arimidex)
                (-RRB-:[115..116] -RRB-))))))
    (::[116..118] --)
    (NP (PRP$:[118..121] its)
      (NML
        (NML (JJ:[122..127] basic)
          (NML-1 (-NONE-:[127..127] *P*)))
        (CC:[129..132] and)
        (NML (JJ:[133..141] clinical)
          (NML-1 (NNS:[142..149] studies)))))
    (-RRB-:[149..150] -RSB-)))

;section 2 Span:154..175
;[Article in Japanese]
(SEC
  (FRAG (NNS:[154..162] -LSB-Article) (IN:[163..165] in)
        (JJ:[166..174] Japanese) (NNS:[174..175] -RSB-)))

;section 3 Span:179..192
;Tsukagoshi S.
(SEC
  (FRAG (NNP:[179..189] Tsukagoshi) (NNP:[190..192] S.)))

;section 4 Span:196..254
;Cancer Institute, Japanese Foundation for Cancer Research.
(SEC
  (FRAG (NNP:[196..202] Cancer) (NNP:[203..212] Institute) (,:[212..213] ,)
        (NNP:[214..222] Japanese) (NNP:[223..233] Foundation)
        (IN:[234..237] for) (NNP:[238..244] Cancer) (NNP:[245..253] Research)
        (.:[253..254] .)))

;sentence 5 Span:258..384
;Anastrozole (JAN), developed by Zeneca UK (presently AstraZeneca UK), is a
;new  aromatase inhibitor which belongs to triazole.
;[258..269]:substance:"Anastrozole"
;[271..274]:substance:"JAN"
;[338..347]:cyp450:"aromatase"
;[348..357]:substance:"inhibitor"
;[375..383]:substance:"triazole"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[258..269] Anastrozole)
        (PRN (-LRB-:[270..271] -LRB-)
          (NP (NN:[271..274] JAN))
          (-RRB-:[274..275] -RRB-)))
      (,:[275..276] ,)
      (VP (VBN:[277..286] developed)
        (NP (-NONE-:[286..286] *))
        (PP (IN:[287..289] by)
          (NP-LGS (NNP:[290..296] Zeneca) (NNP:[297..299] UK)
            (PRN (-LRB-:[300..301] -LRB-)
              (FRAG
                (ADVP (RB:[301..310] presently))
                (NP (NNP:[311..322] AstraZeneca) (NNP:[323..325] UK)))
              (-RRB-:[325..326] -RRB-))))))
    (,:[326..327] ,)
    (VP (VBZ:[328..330] is)
      (NP-PRD
        (NP (DT:[331..332] a) (JJ:[333..336] new) (NN:[338..347] aromatase)
            (NN:[348..357] inhibitor))
        (SBAR
          (WHNP-1 (WDT:[358..363] which))
          (S
            (NP-SBJ-1 (-NONE-:[363..363] *T*))
            (VP (VBZ:[364..371] belongs)
              (PP-CLR (TO:[372..374] to)
                (NP (NN:[375..383] triazole))))))))
    (.:[383..384] .)))

;sentence 6 Span:385..497
;Anastrozole shows selective  aromatase inhibition and negligible effects on
;other steroid hormone  biosyntheses.
;[385..396]:substance:"Anastrozole"
;[414..423]:cyp450:"aromatase"
;[467..482]:substance:"steroid hormone"
(SENT
  (S
    (NP-SBJ (NN:[385..396] Anastrozole))
    (VP (VBZ:[397..402] shows)
      (NP
        (NP (JJ:[403..412] selective) (NN:[414..423] aromatase)
            (NN:[424..434] inhibition))
        (CC:[435..438] and)
        (NP
          (NP (JJ:[439..449] negligible) (NNS:[450..457] effects))
          (PP (IN:[458..460] on)
            (NP (JJ:[461..466] other)
               (JJ:[467..474] steroid) (NN:[475..482] hormone)
              (NNS:[484..496] biosyntheses))))))
    (.:[496..497] .)))

;sentence 7 Span:498..596
;The daily dose of 3 mg/kg anastrozole inhibited the growth of DMBA  mammary
;tumours significantly.
;[516..517]:quantitative-value:"3"
;[518..523]:quantitative-units:"mg/kg"
;[524..535]:substance:"anastrozole"
;[560..564]:substance:"DMBA"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[498..501] The) (JJ:[502..507] daily) (NN:[508..512] dose))
      (PP (IN:[513..515] of)
        (NP
          (NML
            (NML (CD:[516..517] 3) (NN:[518..520] mg))
            (PP (SYM:[520..521] /)
              (NP (NN:[521..523] kg))))
          (NN:[524..535] anastrozole))))
    (VP (VBD:[536..545] inhibited)
      (NP
        (NP (DT:[546..549] the) (NN:[550..556] growth))
        (PP (IN:[557..559] of)
          (NP (NN:[560..564] DMBA) (JJ:[566..573] mammary)
              (NNS:[574..581] tumours))))
      (ADVP (RB:[582..595] significantly)))
    (.:[595..596] .)))

;sentence 8 Span:597..785
;Anastrozole inhibited the tumor growth at 5  micrograms/mouse/day (s.c.) in
;androstenedione-treated ovariectomized nude mice  inoculated with MCF-7CA
;cells transfected with aromatase gene.
;[597..608]:substance:"Anastrozole"
;[639..640]:quantitative-value:"5"
;[642..662]:quantitative-units:"micrograms/mouse/day"
;[673..688]:substance:"androstenedione"
(SENT
  (S
    (NP-SBJ (NN:[597..608] Anastrozole))
    (VP (VBD:[609..618] inhibited)
      (NP (DT:[619..622] the) (NN:[623..628] tumor) (NN:[629..635] growth))
      (PP (IN:[636..638] at)
        (NP
          (NP (CD:[639..640] 5) (NNS:[642..652] micrograms))
          (PP (SYM:[652..653] /)
            (NP (NN:[653..658] mouse)))
          (PP (SYM:[658..659] /)
            (NP (NN:[659..662] day)))
          (PRN (-LRB-:[663..664] -LRB-)
            (ADVP (RB:[664..668] s.c.))
            (-RRB-:[668..669] -RRB-))))
      (PP-LOC (IN:[670..672] in)
        (NP
          (NP
            (ADJP (NN:[673..688] androstenedione) (HYPH:[688..689] -)
                  (VBN:[689..696] treated))
            (VBN:[697..711] ovariectomized) (JJ:[712..716] nude)
             (NNS:[717..721] mice))
          (VP (VBN:[723..733] inoculated)
            (NP (-NONE-:[733..733] *))
            (PP-MNR (IN:[734..738] with)
              (NP
                (NP (NN:[739..746] MCF-7CA) (NNS:[747..752] cells))
                (VP (VBN:[753..764] transfected)
                  (NP (-NONE-:[764..764] *))
                  (PP-MNR (IN:[765..769] with)
                    (NP (NN:[770..779] aromatase) (NN:[780..784] gene))))))))))
    (.:[784..785] .)))

;sentence 9 Span:786..914
;In the Japanese  Phase IIa study, the response rate was 27.8% (10/36) in the
;0.5 mg group, and  38.2% (13/34) in the 1 mg group.
;[842..847]:quantitative-value:"27.8%"
;[863..866]:quantitative-value:"0.5"
;[867..869]:quantitative-units:"mg"
;[882..887]:quantitative-value:"38.2%"
;[903..904]:quantitative-value:"1"
;[905..907]:quantitative-units:"mg"
(SENT
  (S
    (PP (IN:[786..788] In)
      (NP (DT:[789..792] the) (JJ:[793..801] Japanese)
        (NML (NN:[803..808] Phase) (NN:[809..812] IIa))
        (NN:[813..818] study)))
    (,:[818..819] ,)
    (NP-SBJ (DT:[820..823] the) (NN:[824..832] response) (NN:[833..837] rate))
    (VP
      (VP (VBD:[838..841] was)
        (NP-PRD=1
           (CD:[842..846] 27.8) (NN:[846..847] %)
          (PRN (-LRB-:[848..849] -LRB-)
            (NP
              (NP (CD:[849..851] 10))
              (PP (SYM:[851..852] /)
                (NP (CD:[852..854] 36))))
            (-RRB-:[854..855] -RRB-)))
        (PP=2 (IN:[856..858] in)
          (NP (DT:[859..862] the)
            (NML (CD:[863..866] 0.5) (NN:[867..869] mg))
            (NN:[870..875] group))))
      (VP (,:[875..876] ,) (CC:[877..880] and)
        (NP-PRD=1
          (NP
             (CD:[882..886] 38.2) (NN:[886..887] %)
            (PRN (-LRB-:[888..889] -LRB-)
              (NP
                (NP (CD:[889..891] 13))
                (PP (SYM:[891..892] /)
                  (NP (CD:[892..894] 34))))
              (-RRB-:[894..895] -RRB-))))
        (PP=2 (IN:[896..898] in)
          (NP (DT:[899..902] the)
            (NML (CD:[903..904] 1) (NN:[905..907] mg))
            (NN:[908..913] group)))))
    (.:[913..914] .)))

;sentence 10 Span:915..1044
;The most common adverse drug reactions were  leucopenia in the 0.5 mg group,
;and LDH increased and leucopenia in the 1 mg  group.
;[939..943]:substance:"drug"
;[978..981]:quantitative-value:"0.5"
;[982..984]:quantitative-units:"mg"
;[996..999]:substance:"LDH"
;[1032..1033]:quantitative-value:"1"
;[1034..1036]:quantitative-units:"mg"
(SENT
  (S
    (NP-SBJ (DT:[915..918] The)
      (ADJP (RBS:[919..923] most) (JJ:[924..930] common))
      (JJ:[931..938] adverse) (NN:[939..943] drug) (NNS:[944..953] reactions))
    (VP
      (VP (VBD:[954..958] were)
        (NP-PRD=1 (NN:[960..970] leucopenia))
        (PP=2 (IN:[971..973] in)
          (NP (DT:[974..977] the)
            (NML (CD:[978..981] 0.5) (NN:[982..984] mg))
            (NN:[985..990] group))))
      (,:[990..991] ,) (CC:[992..995] and)
      (VP
        (NP-PRD=1
          (NP
            (NP (NN:[996..999] LDH))
            (VP (VBN:[1000..1009] increased)
              (NP (-NONE-:[1009..1009] *))))
          (CC:[1010..1013] and)
          (NP (NN:[1014..1024] leucopenia)))
        (PP=2 (IN:[1025..1027] in)
          (NP (DT:[1028..1031] the)
            (NML (CD:[1032..1033] 1) (NN:[1034..1036] mg))
            (NN:[1038..1043] group)))))
    (.:[1043..1044] .)))

;sentence 11 Span:1045..1196
;There were no early deaths, other serious adverse events, or adverse drug 
;reactions of grade 3 or above in this trial; anastrozole was well tolerated.
;[1114..1118]:substance:"drug"
;[1165..1176]:substance:"anastrozole"
(SENT
  (S
    (S
      (NP-SBJ (EX:[1045..1050] There))
      (VP (VBD:[1051..1055] were)
        (NP-PRD (DT:[1056..1058] no)
          (NML
            (NML (JJ:[1059..1064] early) (NNS:[1065..1071] deaths))
            (,:[1071..1072] ,)
            (NML (JJ:[1073..1078] other) (JJ:[1079..1086] serious)
                 (JJ:[1087..1094] adverse) (NNS:[1095..1101] events))
            (,:[1101..1102] ,) (CC:[1103..1105] or)
            (NML
              (NP (JJ:[1106..1113] adverse) (NN:[1114..1118] drug)
                  (NNS:[1120..1129] reactions))
              (PP (IN:[1130..1132] of)
                (UCP
                  (NP (NN:[1133..1138] grade) (CD:[1139..1140] 3))
                  (CC:[1141..1143] or)
                  (ADVP (RB:[1144..1149] above)))))))
        (PP (IN:[1150..1152] in)
          (NP (DT:[1153..1157] this) (NN:[1158..1163] trial)))))
    (::[1163..1164] ;)
    (S
      (NP-SBJ-1 (NN:[1165..1176] anastrozole))
      (VP (VBD:[1177..1180] was)
        (ADVP (RB:[1181..1185] well))
        (VP (VBN:[1186..1195] tolerated)
          (NP-1 (-NONE-:[1195..1195] *)))))
    (.:[1195..1196] .)))

;sentence 12 Span:1197..1395
;In  the Japanese Phase IIb study, the response rates were 33.3% (117/351
;patients)  and 32.8% (114/348 patients) for anastrozole and tamoxifen,
;respectively,  showing non-inferiority of anastrozole.
;[1255..1260]:quantitative-value:"33.3%"
;[1285..1290]:quantitative-value:"32.8%"
;[1314..1325]:substance:"anastrozole"
;[1330..1339]:substance:"tamoxifen"
;[1383..1394]:substance:"anastrozole"
(SENT
  (S
    (PP (IN:[1197..1199] In)
      (NP (DT:[1201..1204] the) (JJ:[1205..1213] Japanese)
        (NML (NN:[1214..1219] Phase) (NN:[1220..1223] IIb))
        (NN:[1224..1229] study)))
    (,:[1229..1230] ,)
    (NP-SBJ (DT:[1231..1234] the) (NN:[1235..1243] response)
            (NNS:[1244..1249] rates))
    (VP (VBD:[1250..1254] were)
      (NP-PRD
        (NP
           (CD:[1255..1259] 33.3) (NN:[1259..1260] %)
          (PRN (-LRB-:[1261..1262] -LRB-)
            (NP
              (NP (CD:[1262..1265] 117))
              (PP (SYM:[1265..1266] /)
                (NP (CD:[1266..1269] 351) (NNS:[1270..1278] patients))))
            (-RRB-:[1278..1279] -RRB-)))
        (CC:[1281..1284] and)
        (NP
           (CD:[1285..1289] 32.8) (NN:[1289..1290] %)
          (PRN (-LRB-:[1291..1292] -LRB-)
            (NP
              (NP (CD:[1292..1295] 114))
              (PP (SYM:[1295..1296] /)
                (NP (CD:[1296..1299] 348) (NNS:[1300..1308] patients))))
            (-RRB-:[1308..1309] -RRB-))))
      (PP (IN:[1310..1313] for)
        (NP (NN:[1314..1325] anastrozole) (CC:[1326..1329] and)
            (NN:[1330..1339] tamoxifen)))
      (,:[1339..1340] ,)
      (ADVP (RB:[1341..1353] respectively))
      (,:[1353..1354] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[1354..1354] *))
        (VP (VBG:[1356..1363] showing)
          (NP
            (NP (AFX:[1364..1367] non) (HYPH:[1367..1368] -)
                (NN:[1368..1379] inferiority))
            (PP (IN:[1380..1382] of)
              (NP (NN:[1383..1394] anastrozole)))))))
    (.:[1394..1395] .)))

;sentence 13 Span:1396..1512
;The median time to disease progression  (TTP) was 251 days and 252 days for
;anastrozole and tamoxifen, respectively.
;[1437..1440]:quantitative-name:"TTP"
;[1446..1449]:quantitative-value:"251"
;[1450..1454]:quantitative-units:"days"
;[1459..1462]:quantitative-value:"252"
;[1463..1467]:quantitative-units:"days"
;[1472..1483]:substance:"anastrozole"
;[1488..1497]:substance:"tamoxifen"
(SENT
  (S
    (NP-SBJ (DT:[1396..1399] The) (JJ:[1400..1406] median)
      (NML
        (NML
          (NML (NN:[1407..1411] time))
          (PP (TO:[1412..1414] to)
            (NP (NN:[1415..1422] disease) (NN:[1423..1434] progression))))
        (NML (-LRB-:[1436..1437] -LRB-) (NN:[1437..1440] TTP)
             (-RRB-:[1440..1441] -RRB-))))
    (VP (VBD:[1442..1445] was)
      (NP-TMP-PRD
        (NP (CD:[1446..1449] 251) (NNS:[1450..1454] days))
        (CC:[1455..1458] and)
        (NP (CD:[1459..1462] 252) (NNS:[1463..1467] days)))
      (PP (IN:[1468..1471] for)
        (NP (NN:[1472..1483] anastrozole) (CC:[1484..1487] and)
            (NN:[1488..1497] tamoxifen)))
      (,:[1497..1498] ,)
      (ADVP (RB:[1499..1511] respectively)))
    (.:[1511..1512] .)))

;sentence 14 Span:1514..1601
;Group comparison using a Cox regression model revealed non-inferiority of 
;anastrozole.
;[1589..1600]:substance:"anastrozole"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1514..1519] Group) (NN:[1520..1530] comparison))
      (VP (VBG:[1531..1536] using)
        (NP (DT:[1537..1538] a) (NNP:[1539..1542] Cox)
            (NN:[1543..1553] regression) (NN:[1554..1559] model))))
    (VP (VBD:[1560..1568] revealed)
      (NP
        (NP (AFX:[1569..1572] non) (HYPH:[1572..1573] -)
            (NN:[1573..1584] inferiority))
        (PP (IN:[1585..1587] of)
          (NP (NN:[1589..1600] anastrozole)))))
    (.:[1600..1601] .)))

;sentence 15 Span:1602..1708
;Therefore, anastrozole was found to be at least as effective as  tamoxifen
;(in the response rate and TTP).
;[1613..1624]:substance:"anastrozole"
;[1667..1676]:substance:"tamoxifen"
;[1703..1706]:quantitative-name:"TTP"
(SENT
  (S
    (ADVP (RB:[1602..1611] Therefore))
    (,:[1611..1612] ,)
    (NP-SBJ-1 (NN:[1613..1624] anastrozole))
    (VP (VBD:[1625..1628] was)
      (VP (VBN:[1629..1634] found)
        (S
          (NP-SBJ-1 (-NONE-:[1634..1634] *))
          (VP (TO:[1635..1637] to)
            (VP (VB:[1638..1640] be)
              (ADJP-PRD
                (ADJP
                  (ADVP (IN:[1641..1643] at) (RBS:[1644..1649] least))
                  (RB:[1650..1652] as) (JJ:[1653..1662] effective))
                (PP (IN:[1663..1665] as)
                  (NP (NN:[1667..1676] tamoxifen))))
              (PRN (-LRB-:[1677..1678] -LRB-)
                (PP (IN:[1678..1680] in)
                  (NP
                    (NP (DT:[1681..1684] the) (NN:[1685..1693] response)
                        (NN:[1694..1698] rate))
                    (CC:[1699..1702] and)
                    (NP (NN:[1703..1706] TTP))))
                (-RRB-:[1706..1707] -RRB-)))))))
    (.:[1707..1708] .)))

;sentence 16 Span:1709..1853
;In US study compared anastrozole with  tamoxifen, TTP with anastrozole is a
;significantly longer than that of tamoxifen  (p = 0.005, two-sides).
;[1730..1741]:substance:"anastrozole"
;[1748..1757]:substance:"tamoxifen"
;[1759..1762]:quantitative-name:"TTP"
;[1768..1779]:substance:"anastrozole"
;[1819..1828]:substance:"tamoxifen"
(SENT
  (S
    (PP (IN:[1709..1711] In)
      (NP
        (NP (NNP:[1712..1714] US) (NN:[1715..1720] study))
        (VP (VBD:[1721..1729] compared)
          (NP (NN:[1730..1741] anastrozole))
          (PP-CLR (IN:[1742..1746] with)
            (NP (NN:[1748..1757] tamoxifen))))))
    (,:[1757..1758] ,)
    (NP-SBJ
      (NP (NN:[1759..1762] TTP))
      (PP (IN:[1763..1767] with)
        (NP (NN:[1768..1779] anastrozole))))
    (VP (VBZ:[1780..1782] is)
      (ADJP-PRD
        (ADJP (DT:[1783..1784] a) (RB:[1785..1798] significantly)
              (JJR:[1799..1805] longer))
        (PP (IN:[1806..1810] than)
          (NP
            (NP (DT:[1811..1815] that))
            (PP (IN:[1816..1818] of)
              (NP (NN:[1819..1828] tamoxifen))))))
      (PRN (-LRB-:[1830..1831] -LRB-)
        (FRAG
          (S
            (NP-SBJ (NN:[1831..1832] p))
            (VP (SYM:[1833..1834] =)
              (NP (CD:[1835..1840] 0.005))))
          (,:[1840..1841] ,)
          (NP (CD:[1842..1845] two) (HYPH:[1845..1846] -)
              (NNS:[1846..1851] sides)))
        (-RRB-:[1851..1852] -RRB-)))
    (.:[1852..1853] .)))

;sentence 17 Span:1854..1992
;Anastrozole has shown to be at least as effective as  tamoxifen, standard
;endocrine therapy for breast cancer, with good safety  profiles.
;[1854..1865]:substance:"Anastrozole"
;[1908..1917]:substance:"tamoxifen"
(SENT
  (S
    (NP-SBJ-1 (NN:[1854..1865] Anastrozole))
    (VP (VBZ:[1866..1869] has)
      (VP (VBN:[1870..1875] shown)
        (S
          (NP-SBJ-1 (-NONE-:[1875..1875] *))
          (VP (TO:[1876..1878] to)
            (VP (VB:[1879..1881] be)
              (ADJP-PRD
                (ADJP
                  (ADVP (IN:[1882..1884] at) (RBS:[1885..1890] least))
                  (RB:[1891..1893] as) (JJ:[1894..1903] effective))
                (PP (IN:[1904..1906] as)
                  (NP
                    (NP (NN:[1908..1917] tamoxifen))
                    (,:[1917..1918] ,)
                    (NP
                      (NP (JJ:[1919..1927] standard) (JJ:[1928..1937] endocrine)
                          (NN:[1938..1945] therapy))
                      (PP (IN:[1946..1949] for)
                        (NP (NN:[1950..1956] breast) (NN:[1957..1963] cancer)))))))
              (,:[1963..1964] ,)
              (PP (IN:[1965..1969] with)
                (NP (JJ:[1970..1974] good) (NN:[1975..1981] safety)
                    (NNS:[1983..1991] profiles))))))))
    (.:[1991..1992] .)))

;sentence 18 Span:1993..2105
;Thus, anastrozole is a promising first-line endocrine therapy in the 
;treatment of postmenopausal breast cancer.
;[1999..2010]:substance:"anastrozole"
(SENT
  (S
    (ADVP (RB:[1993..1997] Thus))
    (,:[1997..1998] ,)
    (NP-SBJ (NN:[1999..2010] anastrozole))
    (VP (VBZ:[2011..2013] is)
      (NP-PRD (DT:[2014..2015] a) (JJ:[2016..2025] promising)
        (NML (JJ:[2026..2031] first) (HYPH:[2031..2032] -)
             (NN:[2032..2036] line))
        (JJ:[2037..2046] endocrine) (NN:[2047..2054] therapy))
      (PP (IN:[2055..2057] in)
        (NP
          (NP (DT:[2058..2061] the) (NN:[2063..2072] treatment))
          (PP (IN:[2073..2075] of)
            (NP (JJ:[2076..2090] postmenopausal) (NN:[2091..2097] breast)
                (NN:[2098..2104] cancer))))))
    (.:[2104..2105] .)))

;section 19 Span:2109..2127
;Publication Types:
(SEC
  (FRAG (NNP:[2109..2120] Publication) (NNP:[2121..2126] Types)
        (NNP:[2126..2127] :)))

;section 20 Span:2133..2139
;Review
(SEC
  (FRAG (NNP:[2133..2139] Review)))

;section 21 Span:2145..2161
;Review, Tutorial
(SEC
  (FRAG (NNP:[2145..2151] Review) (,:[2151..2152] ,) (NNP:[2153..2161] Tutorial)))

;section 22 Span:2165..2210
;PMID: 11329794 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2165..2169] PMID) (::[2169..2170] :) (CD:[2171..2179] 11329794)
        (IN:[2180..2181] -LSB-) (NNP:[2181..2187] PubMed) (HYPH:[2188..2189] -)
        (JJ:[2190..2197] indexed) (IN:[2198..2201] for)
        (NNP:[2202..2210] MEDLINE-RSB-)))
